Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04410328 · ClinicalTrials.gov registry record · Phase 3
Aggrenox To Treat Acute Covid-19
A Phase 3 study of Covid19, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 3
- Development phase
- 98
- Enrollment target
- 1
- Study location
NCT04410328 is a Phase 3 study of Covid19 that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 98 participants, below the 2,701-participant average among 94 other Covid19 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04410328, a Phase 3 study of Covid19, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to explore the efficacy of Aggrenox in patients with SARS-CoV-2 infection with symptoms consistent with COVID-19. An anticipated total of 132 participants will be randomly divided almost equally into 2 groups: one group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally along with the standard of care and the other group with receive the standard of care only but no Dipyridamole ER 200mg/ Aspirin 25mg. Participants will be screened, enrolled, receive treatment, and followed for 28 days. The clinical and laboratory outcomes of all the participants enrolled in the study will be evaluated at the end of the study to explore if there is any difference in the outcomes between 2 groups.
Conditions Studied
Interventions
- OTHER Standard of care
- DRUG Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care
Study Locations (1)
New Jersey
- Rutgers New Jersey Medical School University Hospital - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2020-10-21 |
| Est. Completion | 2021-10-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04410328
The ClinicalTrials.gov registry entry for NCT04410328 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,701-participant average among 94 other Covid19 trials with a reported enrollment target (96% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Standard of care is the first listed.
NCT04410328 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT04410328 about?
NCT04410328 is a clinical study titled "Aggrenox To Treat Acute Covid-19". The purpose of this study is to explore the efficacy of Aggrenox in patients with SARS-CoV-2 infection with symptoms consistent with COVID-19. An anticipated total of 132 participants will be randomly divided almost equally into 2 groups: one group will receive Dipyridamole ER 200mg/ Aspirin 25mg or...
What is the current status of trial NCT04410328?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 98 participants. The study started on 2020-10-21. Estimated completion is 2021-10-15.
What conditions does trial NCT04410328 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT04410328?
The interventions under investigation include: Standard of care (OTHER), Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care (DRUG).
Who is sponsoring clinical trial NCT04410328?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04410328 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
COMPLETED · Phase 3
-
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
COMPLETED · Phase 3
-
Contrast Enhanced Ultrasound in COVID-19
COMPLETED · Phase 3
-
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.